An analysis of 2859 patient samples demonstrated that gene alterations, which include mutations, copy number alterations, and structural variants, were limited to below approximately 2% of patients for the genes NF1, KRAS, HRAS, BRAF, MAPK1, JUN, and RAF1 across BC subtypes. The gene discussed is HRAS; the disease is breast cancer.